Diagnostic utility of CD44 standard, CD44v6, and CD44v3-10 expression in adenocarcinomas presenting in serous fluids

Applied Immunohistochemistry and Molecular Morphology

Volumn 15, Issue 4, 2007, Pages 446-450

  Afify, Alaa ^a,b   Pang, Lori ^a   Howell, Lydia ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adenocarcinoma; CD44; Mesothelial cells; Serous fluid

Indexed keywords

ANTIBODY; CD44V ANTIGEN; CD44V3 ANTIGEN; CD44V6 ANTIGEN; HERMES ANTIGEN; PARAFFIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; BREAST ADENOCARCINOMA; CYTOPATHOLOGY; DIAGNOSTIC PROCEDURE; DISEASE MARKER; GASTROINTESTINAL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MESOTHELIUM CELL; METASTASIS; OVARY ADENOCARCINOMA; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROSA; TUMOR CELL;

ADENOCARCINOMA; ANTIGENS, CD44; EXUDATES AND TRANSUDATES; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL;

EID: 37349086491     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000213154.49063.22     Document Type: Article

References (31)

1. Tolg C, Hoffman M, Herrlich P. Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acid Res. 1993;21:1225-1229.
2. Haynes B, Liao H, Patton K. The transmembrane hyaluronate receptor (CD44): multiple functions, multiple forms. Cancer Cells. 1991;3:347-350.
3. Soukka T, Salmi M, Joensuu H. Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells. Cancer Res. 1997;57:2281-2289.
4. Yasuda1 M, Nakano2 K, Yasumoto1 K, et al. CD44: functional relevance to inflammation and malignancy. Histol Histopathol. 2002;17:945-950.
5. Sherman L, Sleeman J, Herrlich P, et al. Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. Curr Opin Cell Biol. 1994;5:726-733.
6. East J, Hart I. CD44 and its role in tumor progression and metastasis. Eur J Cancer. 1993;29:1921-1922.
7. Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol. 2000;24:598-606.
8. Afify A, Michael C, Stern R. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn cytopathol. 2004;32:145-150.
9. Joensuu H, Klemi PJ, Toikkanen S, et al. Glycoprotein CD44 expression and its association with survival in breast cancer. Am J PathoI. 1993;143:867-872.
10. Afify AM, Craig S, Stern R, et al. Expression of hyaluronic acid and its receptors, CD44, CD44v6 in normal, hyperplastic and neoplastic endometrium. Ann Diagn Pathol. 2005;9:312-318.
11. Jacques S, Selvaggi S. Multiple peritoneal cytologies collected during laparotomy for gynecologic malignancy. Diagn Cytopathol. 1991;7:482-486.
12. Hansen R, Caya J, Clowry L. Benign mesothelial proliferation with effusion: clinicopathologic entity that may mimic Malignancy. Am J Med. 1984;77:887-892.
13. Afify A, Stern R, Werness B. Differential expression of CD44S and hyaluronic acid in malignant mesotheliomas, adenocarcinomas and reactive mesothelial hyperplasias. Appl Immunohistochem. 1998;6:11-15.
14. Chhieng DC, Yee H, Cangiarella JF, et al. Use of E-cadherin and CD44 aids in the differentiation between reactive mesothelial cells and carcinoma cells in pelvic washings. Cancer. 2000;90:299-306.
15. Attanoos RL, Webb R, Gibbs AR. CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma. Histopathology. 1997;30:260-263.
16. Cury PM, Butcher DN, Fisher C. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, cal-retinin and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol. 2000;13:107-112.
17. Stamenkovic I, Aruffo A, Amiot M, et al. The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J. 1991;10:343-348.
18. Ingvarsson S, Dahlenborg K, Carlsson R. Co-ligation of CD44 on naive human tonsillar B cells induces progression towards a germinal center phenotype. Int Immunol. 1999;11:739-744.
19. Shield PW, Callan JJ, Devine PL. Markers for metastatic adenocarcinoma in serous effusion specimens. Diagn Cytopathol. 1994;11:237-245.
20. Warnock ML, Stoloff A, Thor A. Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1. Am J Pathol. 1988;133:30-38.
21. Berner H, Davidson B, Berner A. Differential expression of CD44s and CD44v3-10 in adenocarcinoma cells and reactive mesothelial cells in effusions. Virchows Arch. 2000;436:330-335.
22. Diaz LK, Zhou X, Wright ET, et al. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res. 2005;11:3309-3314.
23. Berner HS, Davidson B, Berner A, et al. Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma - diagnostic and prognostic implications. Clin Exp Metastasis. 2000;18:197-202.
24. Akisik E, Bavbek S, Dalay N. CD44 variant exons in leukemia and lymphoma. Pathol Oncol Res. 2002;8:36-40.
25. Wielenga VJ, Heider KH, van den Berg FM, et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993;53:4754-4756.
26. Bourguignon LY, Zhu D, Zhu H. CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression. Front Biosci. 1998;3:637-649.
27. Bourguignon LY, Zhu H, Shao L, et al. CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. J Biol Chem. 2000;275:1829-1838.
28. HER2, promotes human ovarian tumor cell activation. J Biol Chem. 1997;272:27913-27918.
29. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983-3988.
30. Al-Hajj M, Becker MW, Wicha M, et al. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev. 2003;14:43-47.
31. Pontus K, Ernst J, Jan C, et al. Safety and biodistribution of 99 m Technetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin Cancer Res. 2000;8:3046-3055.